🇺🇸 FDA
Pipeline program

olmesartan medoxomil

CS0866-C-J201

Phase 2 small_molecule completed

Quick answer

olmesartan medoxomil for Chronic Glomerulonephritis is a Phase 2 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo
Indication
Chronic Glomerulonephritis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials